Prognostic value of simultaneous expression of p21 and mdm2 in breast carcinomas treated by adjuvant chemotherapy with antracyclin.

Mathoulin-Portier,M P; Viens,P; Cowen,D; Bertucci,F; Houvenaeghel,G; Geneix,J; Puig,B; Bardou,V J; Jacquemier,J

doi:10.3892/or.7.3.675

Prognostic value of simultaneous expression of p21 and mdm2 in breast carcinomas treated by adjuvant chemotherapy with antracyclin.

Authors:
- M P Mathoulin-Portier
- P Viens
- D Cowen
- F Bertucci
- G Houvenaeghel
- J Geneix
- B Puig
- V J Bardou
- J Jacquemier
View Affiliations

Affiliations: Departementes de Pathologie, Institut Paoli-Calmettes, 13009 Marseille, France.
Published online on: May 1, 2000 https://doi.org/10.3892/or.7.3.675
Pages: 675-755

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

One hundred and sixty-two breast carcinomas treated by adjuvant chemotherapy were investigated in immunohistochemistry for expression of p53 and two wild-type p53-regulated induced proteins, mdm2 and p21/waf1. p21 and mdm2 were expression stongly correlated with Ki67 but not with survival. The p53+/p21+, p53+/p21- and p53+/mdm2- phenotypes were associated with the worst prognosis. The p53+/p21+/ mdm2+ tumors were associated with a better outcome than the other phenotypes, they may be tumors expressing wild-type p53 and p21, and a form of mdm2 that might lead to the stabilization of p53. It is suggested that p21/mdm2 expression should be investigated in all cases of p53 positive breast cancer.